Integer Holdings Corporation — Q3 2022 Form 10-Q Summary
Business Context and Reporting Period
Integer is a medical-device outsource manufacturer serving cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets, with additional battery products for energy, military and environmental applications. The company reports Medical and Non-Medical segments. The filing covers the three and nine months ended September 30, 2022, compared with October 1, 2021.
Integer acquired Aran Biomedical on April 6, 2022, for total estimated consideration of $141.3 million, including contingent consideration. Aran is included in the Medical segment. The 2021 acquisition of Oscor also affected current-period comparability.
Financial Performance and Key Metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Sales | $342.7 million | $305.6 million | $1,003.7 million | $908.1 million |
| Gross profit | $86.7 million | $81.9 million | $261.1 million | $255.1 million |
| Gross margin | 25.3% | 26.8% | 26.0% | 28.1% |
| Operating income | $29.3 million | $33.1 million | $84.5 million | $107.0 million |
| Operating margin | 8.5% | 10.8% | 8.4% | 11.8% |
| Net income | $16.1 million | $22.1 million | $48.3 million | $73.0 million |
| Diluted EPS | $0.48 | $0.66 | $1.45 | $2.20 |
| Operating cash flow | Not separately provided | Not separately provided | $64.8 million | $117.4 million |
Q3 sales increased 12.1%, while nine-month sales increased 10.5%. Net income declined 27.2% in Q3 and 33.9% for the first nine months. Margin compression reflected higher wages, freight, supply-chain disruption and manufacturing inefficiencies.
- Q3 Medical sales increased 11.7% to $330.9 million; Non-Medical sales increased 24.5% to $11.8 million.
- For the first nine months, Cardio & Vascular sales rose 17.3% to $513.8 million, Cardiac Rhythm Management & Neuromodulation rose 3.5% to $389.9 million, and Non-Medical sales rose 13.0% to $30.9 million.
- Q3 operating expenses increased 17.8% to $57.5 million; nine-month operating expenses increased 19.3% to $176.6 million.
- Restructuring and other charges were $3.1 million in Q3 and $10.0 million for the first nine months, compared with $2.5 million and $3.7 million, respectively, in the prior-year periods.
- Q3 equity-investment losses were $2.9 million versus a $0.2 million gain in the prior year; nine-month losses were $5.6 million versus $1.9 million of losses in 2021.
Liquidity, Cash Flow and Debt
- Cash and equivalents were $20.2 million at September 30, 2022, compared with $17.9 million at December 31, 2021.
- Working capital was $357.9 million and the current ratio was 2.80.
- Operating cash flow was $64.8 million for the first nine months, down from $117.4 million, primarily because of lower earnings and increased investment in inventory and receivables.
- Capital expenditures were $43.1 million, and acquisition-related investing cash outflows were $126.6 million. Net investing cash usage was $169.1 million.
- Total debt, net of discounts and deferred issuance costs, was $938.6 million, compared with $828.1 million at year-end 2021. The increase primarily funded the Aran acquisition.
- The $400 million revolving facility had $254.2 million of available capacity after $140.3 million of borrowings and $5.5 million of letters of credit.
- The Term Loan A and revolving facility mature in September 2026; Term Loan B matures in September 2028. Reported interest rates at quarter-end were 4.87% for the Term Loan A and revolver and 5.62% for Term Loan B.
- Integer was in compliance with its debt covenants. Reported total net leverage was approximately 3.1 times and interest coverage was approximately 11.0 times.
- Management stated that projected operating cash flow, cash and available revolver capacity are expected to fund working capital, debt service and capital expenditures for the next twelve months.
Material Changes, Outlook and Risks
Management attributed revenue growth to the Oscor acquisition, Aran, recovering product demand and strength in cardiovascular markets. Growth was partly offset by supplier delays, labor constraints and unfavorable foreign-exchange effects. Supplier performance issues reduced Q3 revenue by approximately $15 million and increased manufacturing costs by approximately $4 million.
Integer is exiting certain markets within Advanced Surgical, Orthopedics and Portable Medical. The transition to other suppliers is expected to take three to four years, creating a future risk of declining sales in affected products. Cost-reduction actions initiated in Q3 are expected to generate up to $2.0 million of additional pre-tax cash charges through Q2 2023. Other operational-excellence and strategic-reorganization initiatives are expected to continue through 2025.
Key risks include supply-chain interruptions, raw-material price and availability volatility, dependence on third-party and single-source suppliers, labor shortages, inflation, rising interest rates, foreign-currency movements, customer concentration, acquisition integration, healthcare regulation, product quality and liability matters, cybersecurity, and compliance with debt covenants. The filing reports no new material legal proceedings and no material changes to previously disclosed risk factors other than expanded supplier-related disclosures.
The company provided no specific quantitative revenue or earnings guidance in the filing. The 2022 acquisition purchase-price allocations remain preliminary, and Aran contingent consideration had a September 30 fair value of $8.3 million, with a maximum undiscounted payout of approximately $9.8 million.
Important Facts for Investors to Verify
- Whether supplier constraints, the reported $15 million Q3 revenue impact and approximately $4 million of incremental manufacturing costs persist.
- Whether pricing, productivity and restructuring actions can offset labor, freight, raw-material and other inflationary pressures.
- The pace and ultimate effect of the planned product-market exits on future Advanced Surgical, Orthopedics and Portable Medical revenue.
- Integration performance and final purchase-price allocations for Aran and Oscor, including contingent consideration obligations.
- Debt reduction capacity, floating-rate exposure, covenant headroom and refinancing requirements as maturities approach.
- Working-capital trends, particularly the increase in inventory to $210.5 million and receivables to $216.0 million.
- Foreign-exchange effects, equity-investment volatility and the sustainability of the unusually low effective tax rates of 5.5% in Q3 and 12.8% year to date.